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ABSTRACT
Despite ubiquitous activation in human cancer, essential downstream effector 
pathways of the MYC transcription factor have been difficult to define and target. Using 
a structure/function-based approach, we identified the mitochondrial RNA polymerase 
(POLRMT) locus as a critical downstream target of MYC. The multifunctional POLRMT 
enzyme controls mitochondrial gene expression, a process required both for 
mitochondrial function and mitochondrial biogenesis. We further demonstrate that 
inhibition of this newly defined MYC effector pathway causes robust and selective 
tumor cell apoptosis, via an acute, checkpoint-like mechanism linked to aberrant 
electron transport chain complex assembly and mitochondrial reactive oxygen species 
(ROS) production. Fortuitously, MYC-dependent tumor cell death can be induced by 
inhibiting the mitochondrial gene expression pathway using a variety of strategies, 
including treatment with FDA-approved antibiotics. In vivo studies using a mouse 
model of Burkitt’s Lymphoma provide pre-clinical evidence that these antibiotics can 
successfully block progression of MYC-dependent tumors.
INTRODUCTION
Overexpression of the c-MYC oncogene occurs in 
most human cancers [1]. The MYC transcription factor 
regulates expression of several thousand genes in order to 
drive cell cycle progression and malignant transformation 
[2, 3]. Among this array of MYC targets, it remains 
unclear which genes play an essential role in malignant 
     Priority Research Paper
Oncotarget72396www.impactjournals.com/oncotarget
transformation. The identification of this essential subset 
of MYC targets is important for two main reasons. First, 
they may provide an understanding of which cellular 
pathways and processes MYC regulates to reprogram 
cellular physiology. Second, these targets may serve 
as points of therapeutic intervention in the face of our 
historic inability to target MYC directly. To address this 
knowledge gap, we previously performed a structure-
function based screen to identify MYC targets linked 
to malignant transformation [4]. This screen identified 
a subset of ~20 MYC targets as specifically correlated 
with transformation [4]. Of this small number of genes, 
subsequent empirical analysis has confirmed that several 
play critical roles in the MYC pathway [5, 6]. Among 
the genes identified by this screen was that encoding the 
mitochondrial RNA polymerase (POLRMT), also known 
as mtRNAP. 
POLRMT encodes the rate-limiting RNA 
polymerase enzyme which controls transcription of the 
small, circular mitochondrial genome [7]. POLRMT 
also contributes to mitochondrial gene expression by 
regulating mtDNA replication via generation of RNA 
primers [8], and interacting with the mitochondrial rRNA 
methyltransferase TFB1M to mediate proper assembly of 
the small mitochondrial ribosome subunit [9].
The mitochondrial proteome is encoded by distinct 
nuclear and mitochondrial genomes. It is well-established 
that MYC drives the nuclear-encoded portion of the 
mitochondrial biogenesis program [10, 11]. The discovery 
of POLRMT as an essential target of MYC provides a 
mechanistic explanation for how MYC also regulates 
mitochondrial genome transcription in order to fully 
reprogram mitochondrial function. 
Transport of electrons is one of the essential 
processes within mitochondria and occurs via the five 
complexes of the electron transport chain (ETC). Four 
of these complexes consist of subunits encoded by both 
nuclear- and mitochondrial-encoded genes. Remarkably, 
interference with MYC’s ability to induce mitochondrial 
transcription results in an imbalance in electron transport 
chain complex components, induction of mitochondrial 
ROS and ultimately converts the cellular response to 
MYC activation from cell proliferation to apoptosis. 
These effects are specific to tumor cells harboring MYC 
activation and can be exploited in vivo using tetracycline 
family antibiotics to block mitochondrial translation. 
Inhibition of this pathway fully eradicated tumor 
formation in the Eµ-myc transgenic model of human 
Burkitt’s Lymphoma.
RESULTS
MYC controls transcription of the gene encoding 
the mitochondrial RNA polymerase POLRMT
The oncogenic transcription factor MYC binds to 
several thousand loci in the human genome [12]. However, 
it remains unclear which of these MYC targets are 
essential for MYC function (reviewed in [13]). To refine 
our understanding of MYC targets specifically relevant 
to malignant transformation, we conducted an expression 
profiling screen designed to identify downstream targets 
whose transcriptional activation correlates with cellular 
transformation [4]. We report here that the nuclear-
encoded mitochondrial RNA polymerase gene POLRMT 
is a direct MYC target. In brief, primary human fibroblast 
cells were engineered to express oncogenic levels of MYC 
via a conditional allele in which MYC is fused to a mutated 
portion of the estrogen receptor (ER). This fusion protein 
allows for induction of oncogenic MYC activity upon 
treatment with the estrogen analog 4-hydroxytamoxifen 
(4-OHT) [14]. As validation, the kinetics and absolute 
level of POLRMT induction upon 4-OHT treatment were 
found to be similar to those of the well-characterized MYC 
target gene CAD, whereas the non-target gene PCAF was 
unaffected by MYC activation. (Figure 1A). Supporting 
this, the study which first demonstrated the role of MYC 
in mitochondrial function identified POLRMT as one of 
281 mitochondrial ontology genes among a total of 2679 
MYC responsive genes [11]. 
Levels of ectopic MYC used in Figure 1A mimic 
those in human tumors where MYC is amplified or 
translocated. To more rigorously assess the physiological 
relevance of POLRMT induction, we examined whether 
endogenous MYC also regulates POLRMT transcription. 
For this purpose, endogenous MYC was depleted from 
a panel of cell lines from different lineages using both 
genetic and biochemical methods. In order to assess 
POLRMT expression in a variety of cell lines exhibiting 
endogenous MYC overexpression, the human Burkitt’s 
lymphoma cell line Raji was used in addition to the 
epithelial line H1299 to represent a lymphoid model with 
MYC translocation. In the non-small cell lung cancer cell 
line H1299, depletion of MYC via shRNA led to a decrease 
in POLRMT protein (Figure 1B). As an alternative method 
of depleting endogenous MYC levels, cells were treated 
with the BET bromodomain inhibitor JQ1, which inhibits 
MYC protein and transcript levels [15]. In Raji cells, 
treatment with JQ1 led to a decrease in POLRMT mRNA 
and protein, concomitant with decreased MYC (Figure 
1C). Additionally, JQ1 treatment of the primary human 
fibroblast line LG1 and the acute myeloid leukemia cell 
line NOMO-1, the cell lines used to originally characterize 
the effect of JQ1 on MYC expression, led to decreased 
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Figure 1: POLRMT is a direct transcriptional target of the MYC oncoprotein. A. 2091 MYC/ER cells were treated with 
4-hydroxytamoxifen (4-OHT) to induce MYC activity. Cells were harvested at the indicated time points and analyzed by quantitative real-
time PCR (qRT-PCR) to show the kinetics of gene induction. Error bars represent SD, n = 3. B. H1299 cells were infected with lentiviral 
MYC shRNA or Luciferase (Luc) shRNA as a control. Cells were harvested and whole cells lysates were analyzed by Western blot for the 
indicated proteins. C. Raji cells were treated with JQ1 to deplete MYC levels. Cells were harvested and whole cell lysates were analyzed 
by Western blot (left) for the indicated proteins and qRT-PCR (right) for POLRMT expression. Error bars represent SD, n = 3. D. Mammary 
tumors were induced in six week old female bitransgenic MMTV-rtTA;TetO-MYC mice via administration of 2 mg/mL doxycycline in 
drinking water. After mammary tumor formation, doxycycline was withdrawn from the water of 4 mice (MYC OFF) while the other mice 
were maintained on doxycycline (MYC ON). 96 hours after doxycycline withdrawal, tumors were harvested and mRNA analyzed by 
qRT-PCR. Error bars represent SD, n = 4. ***p < .001 Student’s t-test (two-sided). E. Modified image taken from UCSC genome browser 
(Assembly GRCh37/hg19) ENCODE transcription factor ChIP track showing MYC binding at the POLRMT locus in a variety of cell lines 
(http://genome.ucsc.edu).
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levels of POLRMT mRNA (Supplemental Figure S1A). 
Considered together, these data suggest that MYC is an 
essential regulator of the mitochondrial RNA polymerase 
POLRMT in a broad array of tumor cell lineages. 
To assess whether the findings linking MYC 
and POLRMT expression extend to an in vivo setting, 
POLRMT mRNA expression was quantified in tumors 
from a mouse model of MYC-driven mammary cancer. In 
these animals, MYC expression is mammary gland specific 
and doxycycline-inducible [16]. Tumors were induced 
in 6-week old mice and after appearance of palpable 
mammary tumors, a subset of mice were withdrawn from 
doxycycline to inhibit MYC expression. Analysis of 
mRNA levels from harvested tumors demonstrated that 
POLRMT transcript levels tightly correlate with MYC 
activity in vivo, with a significant decrease in POLRMT 
mRNA observed in mice when MYC activity was reduced 
even briefly (Figure 1D). Furthermore, analysis of TCGA 
datasets using the cBioPortal for Cancer Genomics 
indicated a correlation between MYC amplification and/
or increased mRNA expression and increased POLRMT 
mRNA expression in cancer patient samples. For example, 
datasets for glioblastoma and breast invasive carcinoma 
reveal a significant correlation between MYC and 
POLRMT, with p values of < 0.001 and .002, respectively 
[17, 18]. In addition, when analyzed using the Oncomine 
Cancer Profiling Database (www.oncomine.org), both 
MYC and POLRMT, as well as established MYC 
targets LDHA and BAG1, are overexpressed in Burkitt’s 
lymphoma samples compared to normal B lymphocytes 
(Supplemental Figure S1B) [19]. Similarly, several cancer 
types including colorectal cancers, diffuse large B cell 
lymphoma, and multiple myeloma display increased 
POLRMT expression correlated with increased MYC 
expression in cancer cells compared to normal control 
cells (Supplemental Figure S1C) [20-22]. 
Figure 2: MYC regulates mitochondrial transcription and mtDNA replication via POLRMT. A. H1299 cells were 
transfected with MYC siRNA or GFP siRNA as a control. 24 hours post-transfection, one group of MYC depleted cells was infected with 
lentivirus expressing human POLRMT (P) or the empty vector (vec). Three days post-transfection, cells were harvested and mitochondrial 
proteins POLRMT, TFAM, HSP60 and Porin were measured from purified mitochondria. The level of MYC depletion was evaluated from 
whole cell lysates. B. Cells described in (A) were analyzed by qRT-PCR for mitochondrial gene expression. Nuclear gene SMYD2 was used 
as a control. Error bars represent SD, n = 3. C. Map of the human mitochondrial genome indicating ORF, tRNA, rRNA and gene locations. 
Locations of the primer sets used for quantifying mtDNA genome in (D) are indicated (red bars labeled 1-5). D. Total cellular DNA from 
cells described in (A) was quantified by qPCR using primer sets shown in (C). Primers amplifying a region at 3p24 were used to validate 
the specificity of the mitochondrial/nuclear comparison. Error bars represent SD, n = 3.
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To address whether POLRMT represents a primary 
target of MYC, the binding of endogenous MYC to the 
POLRMT locus was evaluated. Within the genomic 
sequence of POLRMT, several matches to the consensus 
high-affinity binding site (E-box) for MYC/MAX dimers 
were identified. In silico analysis of the ENCODE 
transcription factor track in the UCSC genome browser 
showed MYC binding at multiple E-box sequences within 
the POLRMT locus in a variety of human cell types 
(Figure 1E) [23, 24]. The direct binding of MYC to the 
Figure 3: Synthetic Lethal Dependency of Deregulated MYC on POLRMT. A. U2OS MYC/ER cells were infected with 
lentiviral POLRMT shRNA or Luciferase (Luc) shRNA as a control. Five days post-infection cells were seeded at equal densities and MYC 
activity was induced via treatment with 4-OHT (MYC On). Cells were counted on day three and day five post MYC-activation. shPOLRMT 
cell counts are shown with an adjusted scale (right). Error bars represent SD, n = 3. ***p < .001, Unpaired t-test. B. U2OS MYC/ER cells 
were depleted of POLRMT and treated with 4-OHT (MYC On), as in (A). Cells were harvested on day three post MYC-activation and 
stained with Annexin V and 7-AAD. A representative flow cytometry analysis (left) and quantification of the percent Annexin V positive 
cells (right) are shown. Error bars represent SEM, n = 18. ***p < .001; n.s., not significant, Unpaired t-test. C. U2OS MYC/ER cells were 
infected with two distinct lentiviral POLRMT shRNA plasmids (P1 and P2) or shLuc. Five days post-infection MYC was activated via 
treatment with 4-OHT (MYC On). Cells were harvested three days post MYC activation and whole cell lysates were analyzed by Western 
blot for the indicated proteins. D. HCT116 cells were infected with lentiviral POLRMT shRNA and/or MYC shRNA, or Luciferase shRNA. 
Five days post-infection cells were harvested and stained with Annexin V and 7-AAD. A representative flow cytometry analysis (left) and 
quantification of percent of Annexin V positive cells (right) is shown. Error bars represent SEM, n = 3. **p < .01; n.s., not significant, 
Unpaired t-test. E. Whole cell lysates of cells described in (D) were analyzed by Western blot for the indicated proteins. Casp-3, caspase-3; 
FL, full length; CL, cleaved.
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POLRMT locus is also supported by genome-wide studies 
in murine embryonic stem cells showing occupancy of this 
region 5’ of the POLRMT locus by MYC, using ChIP-
seq [25]. We empirically confirmed specific recruitment 
of endogenous MYC to these sites by ChIP in the primary 
human fibroblast cell line 2091 (Supplemental Figure 
S1D).
MYC controls mitochondrial transcription and 
mitochondrial genome content via POLRMT 
induction
As discussed, POLRMT catalyzes transcription 
of the 16.6kb mitochondrial genome. To determine 
whether MYC controls mitochondrial gene expression 
via POLRMT induction, expression of a panel of 
mitochondrial genes was assessed in H1299 cells. Western 
blot analysis of mitochondrial lysates from these cells 
confirmed that MYC depletion resulted in the loss of 
POLRMT (Figure 2A). MYC knockdown also resulted 
in a partial loss of the mitochondrial transcription factor 
TFAM, an established MYC target [11]. Decreases in 
POLRMT and TFAM were not a result of a general 
defect in the importation of nuclear-encoded proteins 
into the mitochondria, since HSP60 protein levels in 
the mitochondria were not affected by MYC depletion. 
In order to assess whether the MYC-dependent loss of 
POLRMT results in a defect in mitochondrial transcription, 
qRT-PCR was performed for the mitochondrial-encoded 
genes ND2, ND4, CytB, ATP6 and 12S, as well as the 
nuclear gene SMYD2 (Figure 2B). This analysis revealed 
that depletion of MYC caused a decrease in all five of 
the mitochondrial transcripts assessed. SMYD2, which 
is not a MYC target, was unaffected by MYC depletion. 
In MYC-depleted cells, restoring POLRMT levels by 
ectopic expression (Figure 2A) was sufficient to rescue 
the mitochondrial transcripts to normal levels (Figure 2B), 
confirming that POLRMT is the limiting factor in their 
expression. 
MYC regulates mitochondrial biogenesis [11], 
a process that requires increased mitochondrial DNA 
Figure 4: Synthetic lethality can be induced via treatment with 2’C Methyladenosine (2’CMeA). A. U2OS MYC/ER cells 
were treated with increasing concentrations of 2’CMeA, as indicated. MYC activity was induced via treatment with 4-OHT (MYC On). 
Three days post MYC-activation cells were harvested and stained with Annexin V and 7-AAD (left). Quantification of percent Annexin 
V positive cells at 30µM 2’CMeA dose is shown (middle). Expression of mitochondrial transcript ND4 was assessed by qRT-PCR (right). 
Error bars represent SEM (middle) and SD (right), n = 7. *p< .01; n.s. not significant, Unpaired t-test. B. HCT116 cells were infected with 
lentiviral MYC shRNA or Luciferase (Luc) shRNA and treated with 30µM 2’CMeA. Cells were harvested and stained with Annexin V and 
7-AAD. A representative flow cytometry analysis (left) and quantification of percent Annexin V positive cells (middle) are shown. Whole 
cell lysates were analyzed by Western blot for the indicated proteins (right). Error bars represent SEM, n = 3. *p < .01; n.s., not significant, 
Unpaired t-test. Casp-3, caspase-3; FL, full length; CL, cleaved; UT, untreated.
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(mtDNA) synthesis. In addition to its role in gene 
expression, POLRMT also primes mtDNA replication [26, 
27], contributing to formation of the D loop structure at the 
major origin of DNA replication within the mitochondrial 
genome [28]. This raises the possibility that POLRMT 
induction might explain the role of MYC in mitochondrial 
genome replication. In support of this model, MYC-
depleted H1299 cells displayed a significant decrease 
in mitochondrial genome content when assessed at five 
independent regions of the mitochondrial genome (Figure 
2C and 2D). Upon expression of ectopic POLRMT, 
mitochondrial genome content was fully rescued. In 
contrast, nuclear DNA content was unaffected by MYC 
depletion or POLRMT expression, as quantified at the 
control locus 3p24.
POLRMT inhibition is synthetically lethal with 
oncogenic levels of MYC
As described earlier, POLRMT was identified 
in a screen for MYC targets correlated with malignant 
transformation [4]. To assess the functional requirement 
for POLRMT as a downstream MYC effector, the extent 
to which MYC-overexpressing cells require POLRMT 
was tested. A human osteosarcoma line U2OS expressing 
a conditional MYC/ER allele was used for this analysis, 
as these cells display robust MYC-dependent changes 
in either cell proliferation or apoptosis, depending on 
cellular contexts [29]. POLRMT was depleted from these 
cells using shRNA and cells were plated at equal numbers 
prior to MYC activation via treatment with 4-OHT. 
Over the course of 5 days, cell numbers were quantified 
(Figure 3A). The cells used in this experiment proliferate 
rapidly independent of MYC/ER activity. As expected, 
activation of MYC resulted in a small increase in cell 
number. In contrast, in cells where POLRMT induction 
was blocked, activation of MYC resulted in a substantial 
decrease in cell number. Apoptosis assays (both Annexin 
V staining and Western blotting for caspase-3 cleavage) 
demonstrated that this decrease in cell number resulted 
from a significant increase in apoptosis under conditions 
of MYC activation and POLRMT depletion (Figures 
3B, 3C and S2A). Depletion of POLRMT without MYC 
activation slowed proliferation, but did not significantly 
affect cell viability (Figure 3A and 3B). Thus, loss of 
POLRMT induction was synthetically lethal only with 
oncogenic levels of MYC activation. These observations 
were consistent over the course of multiple experiments, 
using multiple shRNA molecules to target POLRMT 
(Figures 3B and 3C). Though levels of apoptosis are less 
than 100%, a clonogenic assay was performed to assess 
the replicative potential of surviving cells. Consistent with 
the proliferation assay discussed above, the remaining 
cells under synthetic lethal conditions did not exhibit 
significant replicative potential (data not shown).
While the conditional MYC/ER allele has been used 
extensively to mimic oncogenic levels of MYC function 
[14, 30], it was also important to assess the relevance 
of POLRMT under more physiological conditions. For 
this purpose, HCT116 colon carcinoma cells, which 
express high levels of endogenous MYC (Supplemental 
Figure S2B), were depleted of POLRMT, MYC, or both 
POLRMT and MYC using shRNA. Levels of apoptosis 
were then analyzed (Figures 3D and 3E). Annexin V 
staining revealed that cells with low POLRMT expression 
and high endogenous MYC displayed increased apoptosis 
(Figure 3D). Furthermore, depletion of MYC in addition 
to depletion of POLRMT rescued cell viability to a normal 
level. Apoptosis was also observed upon POLRMT 
depletion, as assessed using caspase-3 cleavage and PARP 
cleavage as markers (Figure 3E). As with Annexin V 
staining, apoptosis measured by caspase-3 cleavage and 
PARP cleavage were reduced upon depletion of MYC. To 
further extend these findings in another cell line expressing 
high endogenous MYC, Raji Burkitt’s lymphoma cells 
were depleted of POLRMT using shRNA. In these cells, 
MYC is expressed at very high levels due to chromosomal 
translocation [31]. Consistent with the observations made 
in HCT116 cells, a decrease in POLRMT expression 
in combination with oncogenic, endogenous MYC 
expression led to increased apoptosis in Raji cells, as 
evaluated by Annexin V staining (Supplemental Figures 
S2C and S2D). These data confirm that POLRMT 
depletion is synthetically lethal with oncogenic levels of 
MYC, in a variety of human cancer cell lineages.
Synthetic lethality can be induced 
pharmacologically via treatment with 2’CMeA
In humans, very little structural similarity exists 
between POLRMT and the nuclear RNA polymerase 
molecules. Instead, human POLRMT is related to the 
T7 family of prokaryotic enzymes [32-34]. Thus, drugs 
that target POLRMT might have little effect on the other 
human RNA polymerase enzymes. Structural analysis 
and in vitro enzymatic assays show that polymerization 
of RNA by POLRMT is inhibited by 2’-C-methyl-
adenosine (2’CMeA) [35]. Empirical analysis confirmed 
that treatment of U2OS cells with 2’CMeA, which 
is converted efficiently to 2’-C-methyl-ATP once 
taken up by cells, results in a dose-dependent block in 
mitochondrial transcription without a measurable effect 
on nuclear transcription (Supplemental Figure S3A). 
This compound was therefore used to assess whether 
blocking the enzymatic activity of POLRMT via a small 
molecule strategy results in synthetic lethality with MYC 
activation, as was observed when POLRMT levels were 
reduced using shRNA. Treatment of U2OS MYC/ER 
cells with 2’CMeA had no significant effect on viability 
in the absence of MYC activation (Figure 4A). As shown 
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previously, MYC activation also had no significant 
effect on viability (Figures 3B and 4A). However, when 
POLRMT inhibition by 2’CMeA was combined with 
MYC activation, synthetic lethality was observed in 
a dose-dependent manner (Figure 4A). Inhibition of 
POLRMT by 2’CMeA was also synthetically lethal with 
oncogenic levels of endogenous MYC (Figures 4B and 
S3B). HCT116 cells treated with 2’CMeA exhibited high 
levels of apoptosis when MYC was present, while cells 
depleted of MYC by shRNA reverted to a basal level 
of apoptosis. Coupled with the findings from POLRMT 
shRNA studies, these data suggest that MYC activation 
programs the cell to become strictly dependent on an 
essential function of POLRMT for survival.
Inhibition of mitochondrial translation is 
synthetically lethal with oncogenic MYC
In order to identify the essential function provided 
by POLRMT to MYC overexpressing cells, we explored 
the pathway of mitochondrial gene expression at multiple 
points of regulation. As discussed above, POLRMT is the 
rate-limiting enzyme of mitochondrial transcription and 
is also responsible for regulation of mtDNA replication 
[7, 26]. More recently, POLRMT was discovered to play 
a transcription-independent role via its interaction with a 
mitochondrial ribosomal RNA methyltransferase TFB1M 
[9]. The interaction between TFB1M and POLRMT is 
necessary to regulate mitochondrial ribosome assembly, 
and disruption of POLRMT expression leads to changes 
in steady-state levels of mitochondrial-encoded proteins. 
Thus, POLRMT is a critical regulator of mitochondrial 
translation, in addition to its roles in mitochondrial 
transcription and mtDNA replication. To functionally 
dissect the dependence of MYC-overexpressing cells on 
elevated mitochondrial gene expression, we inhibited 
mitochondrial translation in cells with oncogenic levels 
of MYC. Consistent with results using POLRMT shRNA, 
synthetic lethality was phenocopied when the POLRMT 
interaction partner TFB1M was depleted from HCT116 
cells expressing high MYC levels (Figures 5A-5C), but 
there is a lack of significant apoptosis under conditions 
where MYC is depleted. Thus, blocking mitochondrial 
gene expression at the level of translation triggers the 
rapid death of MYC overexpressing cells. Supporting 
this, the Amati group recently found depletion of other 
components of the mitochondrial translation machinery 
to be synthetically lethal with oncogenic MYC, and we 
have also confirmed these results (Supplemental Figure 
S4) [36].
Several classes of antibiotics target bacterial 
ribosomes and prevent protein synthesis [37]. The 
bacterial translation machinery shares homology with 
the mitochondrial translation machinery in humans and 
therefore antibiotics targeting bacterial ribosomes also 
effect human mitochondrial ribosomes and mitochondrial 
protein synthesis [38]. Fortuitously, several FDA-
approved antibiotics work via this mechanism. Supporting 
this as a potential therapeutic strategy in human cancer, 
recent studies have shown that targeting mitochondrial 
translation (and transcription) using antibiotics induced 
apoptosis of acute myeloid leukemia (AML) cells [39, 40]. 
However, no link to MYC levels was explored in the AML 
cells and the mechanism responsible for the sensitivity of 
cancer cell lines to blocking mitochondrial translation 
was not determined. In order to gain mechanistic insight 
into the apoptosis we have observed, we explored the 
effect of antibiotics that block mitochondrial translation 
in our MYC-inducible system. Upon MYC activation in 
U2OS MYC/ER cells, apoptosis was induced in response 
to chloramphenicol in a dose dependent manner (Figure 
5D). Similarly, U2OS MYC/ER cells are sensitive to 
tigecycline, only in the presence of activated MYC (Figure 
5E). Collectively, these results demonstrate that MYC-
overexpressing cells are dependent on proper expression 
of mitochondrial encoded proteins for cell survival, a 
dependency that can be exploited using antibiotics to 
selectively induce the death of tumor cells expressing 
oncogenic levels of MYC. 
Tigecycline effectively reduces tumor burden in 
vivo
Results showing that the FDA-approved drugs 
chloramphenicol and tigecycline can be used to 
target MYC-driven cancer cells in vitro prompted an 
examination of the effect of this treatment in vivo. 
Tigecycline is in wide clinical use [41] and has recently 
completed a Phase I clinical trial for the treatment of 
AML (clinicaltrials.gov ID: NCT01332786), based on 
the pre-clinical data mentioned above [39, 40]. To define 
the role of MYC in this phenomenon, an in vivo model of 
MYC-driven lymphomas was used to test the efficacy of 
tigecycline on preventing tumor progression. Mice were 
inoculated with GFP-expressing Eµ-myc lymphoma cells 
and treated with tigecycline or vehicle control (Figure 
6). The transplantable lymphoma line derives from a 
primary tumor generated in mice which express the Eµ-
MYC transgene which mimics the translocation of MYC 
to the IgH locus that is diagnostic of Burkitt’s lymphoma 
[31, 42]. Mice inoculated intravenously with lymphoma 
cells derived from these primary tumors rapidly develop 
lymphomas and typically succumb to the disease within 
30 days [43, 44]. However, treatment of these mice with 
tigecycline resulted in a dramatic reduction of the tumor 
burden, measured by white blood cell count and GFP-
expressing cell count, and a subsequent improvement 
in overall survival. The experimental design included 
two arms of the study to explore therapeutic as well 
as preventative treatments. Mice were treated with 
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Figure 5: Inhibition of mitochondrial translation phenocopies synthetic lethality resulting from POLRMT inhibition. 
A. HCT116 cells were infected with lentiviral MYC shRNA and/or TFB1M shRNA or Luciferase (Luc) shRNA. Five days post-infection 
cells were harvested and stained with Annexin V and 7-AAD. A representative flow cytometry analysis (left) and quantification of percent 
Annexin V positive cells (right) is shown. Error bars represent SEM, n = 5. *p < .05; n.s., not significant, Unpaired t-test B. Whole cell 
lysates of cells described in (A) were analyzed by Western blot for indicated proteins. C. Relative mRNA expression of cells described in 
(A) was measured by qRT-PCR. Error bars represent SD, n = 5. D. U2OS MYC/ER cells were treated with increasing concentrations of 
chloramphenicol, as indicated. MYC activity was induced via treatment with 4-OHT (MYC On). Three days post MYC-activation cells 
were harvested and stained with Annexin V and 7-AAD (left). Quantification of percent Annexin V positive cells at 40µg/mL dose is shown 
(right). Error bars represent SEM, n = 8. ***p < .0001; n.s., not significant, Unpaired t-test E. U2OS MYC/ER cells were treated with 
10µM tigecycline (Tig) and MYC activity was induced via treatment with 4-OHT (MYC On). Three days post MYC-activation cells were 
harvested and stained with Annexin V and 7-AAD. A representative flow cytometry analysis (left) and quantification of percent Annexin 
V positive staining cells (right) is shown. Error bars represent SEM, n = 7. *p < .05; n.s., not significant, Unpaired t-test. UT, untreated.
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tigecycline either before (Figures 6A-6C) or after 
(Figures 6D-6F) the lymphomas established, as measured 
by white blood cell count. Remarkably, mice treated 
before tumor development displayed 100% survival 
rate for 120 days after lymphoma cells were introduced, 
at which time the study was terminated (Figure 6A). 
Mice treated with tigecycline simultaneous with tumor 
cell inoculation retained a constant and normal number 
of white blood cells, whereas control mice displayed 
a steady increase in white blood cell count, reflecting 
lymphoma progression (Figure 6B). Consistent with this, 
GFP staining showed that control mice displayed a high 
percentage (approximately 60%) of lymphoma cells, while 
mice treated with tigecycline displayed less than 1% GFP-
positive cells in blood samples at 19 days post-inoculation 
(Figures 6C, S5A and S5B). These results demonstrate 
that tigecycline treatment is effective at preventing MYC-
driven lymphoma tumor engraftment and increasing 
survival in vivo. We also explored the therapeutic benefit 
of tigecycline treatment after lymphoma establishment. 
Notably, mice treated with tigecycline after lymphomas 
were established had approximately 70% survival rate 
with little increase in white blood cell count or GFP-
positive cells (Figures 6D-6F, S5A and S5B). We presume 
that the effects of tigecycline on tumor cell survival are 
cell autonomous within the lymphoma cells, but there is 
a possibility the host stroma or immune system contribute 
to the effect of the drug. However, based on results found 
by the Amati group, tigecycline blocks the growth of 
MYC-derived lymphomas in vivo, even in the absence of 
an immune system (D’Andrea et al 2016, accompanying 
paper).
The marked success of tigecycline treatment in 
vivo highlights the potential for using this drug clinically 
to treat patients with MYC-driven tumors. One possible 
constraint of this treatment would be that MYC-dependent 
apoptosis relies on functional p53 in some cases. It was 
therefore worthwhile to determine whether apoptosis 
induced by simultaneous activation of MYC and blockade 
of mitochondrial gene expression requires an intact p53 
pathway. To assess this potential dependency, isogenic 
HCT116 cells were utilized which are either wild-
type or null for p53 [45]. In these cells, which express 
high endogenous MYC levels, depletion of POLRMT 
using two distinct shRNAs resulted in robust induction 
of apoptosis in the presence of p53, as measured by 
caspase-3 cleavage (Supplemental Figure S5C). In cells 
lacking p53 expression, depletion of POLRMT also led 
to an increase in caspase-3 cleavage compared to control 
cells (Supplemental Figure S5C). Though the levels of 
apoptosis were slightly diminished compared to p53 wild 
type cells, it is clear that POLRMT depletion remains 
synthetically lethal with oncogenic MYC regardless of 
p53 status. In vivo support for the p53 independence of 
these effects was provided by the fact that the Eµ-MYC 
lymphoma cells used in Figure 6 lack functional p53 [46], 
yet remain tigecycline sensitive. 
Tight coordination of the nuclear- and 
mitochondrial-encoded components of the 
mitochondrial program driven by MYC is critical 
for tumor cell survival
The results thus far support the hypothesis that 
induction of mitochondrial gene expression is required 
for the survival of MYC-overexpressing cells. In order to 
define the biochemical defect that triggers the apoptosis 
of cells expressing elevated MYC and depressed 
mitochondrial gene expression, several hypotheses 
were explored. One of these hypotheses relates to the 
role of MYC in regulating pyrimidine biosynthesis 
[47]. An essential step in this pathway involves the 
mitochondrial localized dihydrooratate dehydrogenase 
enzyme (DHODH), whose catalytic activity is dependent 
on ubiquinone as an electron acceptor. Dysfunctional 
electron transport chain (ETC) activity prevents 
ubiquinone production, and thereby impedes DHODH 
and pyrimidine biosynthesis. Rho0 cells, which lack 
mtDNA and therefore have defects in DHODH activity 
and pyrimidine biosynthesis, can survive if provided with 
exogenous uridine [48, 49]. To assess whether defective 
DHODH/pyrimidine biosynthesis could explain the 
synthetic lethality between MYC activation and POLRMT 
inhibition, U2OS MYC/ER cells were treated with uridine 
(and pyruvate). Pyruvate is necessary to maintain the 
cellular redox balance, which is altered in cells lacking 
mitochondrial oxidative phosphorylation due to an 
accumulation of NADH. Restoration of a normal redox 
state is achieved during the reaction converting pyruvate 
to lactate, while NADH is oxidized to NAD+ [49]. 
Cells supplemented with exogenous uridine displayed 
comparable levels of apoptosis to non-supplemented cells 
under synthetic lethal conditions (Supplemental Figures 
S6A and S6B), suggesting that a defect in pyrimidine 
biosynthesis is an unlikely trigger for apoptosis. As an 
alternative method to rescue this pathway, the yeast 
form of DHODH was expressed in these cells. The yeast 
DHODH enzyme is cytoplasmic rather than mitochondrial 
and does not require ubiquinone as an electron acceptor 
[50, 51]. Expression of this plasmid circumvents the 
requirement for ETC function in pyrimidine biosynthesis. 
As with the uridine/pyruvate supplementation study, 
expression of yeast DHODH did not reverse the synthetic 
lethality (Supplemental Figure S6D). 
Another biological pathway that links MYC 
to mitochondria is one-carbon metabolism [52-54]. 
The serine hydroxymethyltransferase SHMT2 is a 
mitochondrial localized protein and a direct MYC target 
[52, 55]. In a screen for functional complementation, 
SHMT2 could provide partial rescue of the proliferation 
defect of MYC null cells [52]. We were prompted 
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Figure 6: Tigecycline inhibits B cell lymphoma, in vivo, prolonging survival. A. and D. Kaplan-Meier survival curves of 
C57Bl/6 mice injected intravenously with GFP-expressing Eµ-myc lymphoma cells and administered tigecycline (Tig) or PBS (vehicle 
control) starting the day of injection (A, p < 0.0001, log-rank test) or once the lymphoma had established on day nine indicated by an arrow 
(D, p < 0.0001, log-rank test). B. and E. For the mice in A and D, respectively, white blood cell counts (WBC) and GFP positive cells 
(lymphoma) in the blood, as measured by flow cytometry (C and F, respectively), were determined on the days indicated. The number (n) of 
mice in each group is indicated. B, *P = 4.43x10-6, **P = 1.57x10-5; C, *P = 1.58x10-5; **P = 1.57x10-8; E, *P = 7.23x10-4, **P = 9.42x10-6; 
F, *P = 4.77x10-7; **P = 4.02x10-9; t-tests.
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to explore the possibility that a defect in one-carbon 
metabolism, due to loss of mitochondrial SHMT2 
function, could induce apoptosis in the presence of 
oncogenic MYC. However, depletion of SHMT2 in the 
presence of oncogenic MYC in U2OS MYC/ER cells had 
little effect on cell viability (Supplemental Figure S6E). 
These data suggest that MYC-overexpressing cells are 
not dependent on mitochondrial one-carbon metabolism 
regulated by SHMT2 for survival.
The 13 genes encoded by the mitochondrial genome 
produce subunits of the ETC. Together with nuclear 
encoded subunits, these proteins form Complexes I, 
III, IV and V. As MYC is known to drive mitochondrial 
biogenesis and function, the nuclear encoded subunits of 
the ETC are overexpressed in the presence of oncogenic 
MYC [11]. It is possible that the combinatorial effect of 
increasing production of nuclear encoded subunits (due 
to high MYC), and simultaneous defects in production 
of mitochondrial encoded subunits (e.g. when POLRMT 
is depleted), causes an imbalance in the stoichiometry of 
subunits within individual ETC complexes. Defects in 
proper ETC activity cause release of electrons, thereby 
increasing cellular levels of reactive oxygen species 
(ROS), which are potent inducers of apoptosis [56-58]. 
In order to test the hypothesis that the synthetic lethality 
is triggered by high cellular ROS levels, we treated 
cells with ROS scavengers. U2OS MYC/ER cells were 
depleted of POLRMT and treated with 4-OHT to induce 
MYC activity, resulting in the synthetic lethal phenotype. 
Upon treatment with the ROS scavenger N-Acetyl 
Cysteine (NAC), synthetic lethality was partially reversed 
(Figure 7A). Similarly, induction of synthetic lethality via 
treatment with tigecycline was also rescued with NAC 
(Figure 7B). These results support the hypothesis that 
MYC coordinately regulates nuclear- and mitochondrial-
encoded proteins to form a functional ETC, and that 
disturbing this balances triggers ROS production and 
apoptosis. Thus, cells with oncogenic MYC express high 
levels of nuclear-encoded ETC subunits in order to meet 
the metabolic demand of rapid growth and proliferation, 
but interfering with MYC’s ability to coordinately regulate 
mitochondrial-encoded ETC subunits creates an imbalance 
in stoichiometry, leading to toxic cellular ROS levels and 
apoptosis.
To directly assess whether this imbalance exists, we 
analyzed the protein levels of ETC complex subunits that 
are labile when their resident complex is misassembled. 
As shown in Figure 7C, upon chloramphenicol treatment, 
cells lose stability of Complexes I, III and IV. Complex II 
is entirely nuclear-encoded, and is therefore unaffected by 
inhibition of mitochondrial translation. These observations 
are consistent with the synthetic lethality resulting from 
an imbalance in the stoichiometry of ETC complexes. 
Complex II is therefore overproduced, relative to the other 
complexes, presumably leading to release of electrons 
and increased levels of apoptosis [58]. To more distinctly 
define the source of ROS production, we performed 
synthetic lethality experiments using a ROS scavenger 
specific to mitochondrial-produced ROS. This reagent, 
MnTBAP, is a superoxide dismutase mimetic that targets 
the superoxide molecules produced by free radicals 
created during ETC reactions [59, 60]. As shown by 
caspase-3 cleavage, synthetic lethality was reversed upon 
treatment with MnTBAP (Figure 7D), confirming that 
the source of apoptosis is mitochondrial-produced ROS. 
Additionally, we directly measured levels of mitochondrial 
produced superoxide using the MitoSOX Red assay. As 
shown in Figure S6F, there is an increase in mitochondrial 
superoxide in cells under synthetic lethal conditions. 
Collectively, the data presented in this study indicate 
that MYC-overexpressing cells are reliant on elevated 
mitochondrial gene expression for proper ETC function 
and protection against mitochondrial-produced ROS. We 
have shown that this pathway can be targeted as a means 
to therapeutically treat MYC-driven cancers, both in vitro 
and in vivo. The therapeutic implications of this study are 
heightened by the existence of FDA-approved drugs that 
target this essential pathway.
DISCUSSION
MYC overexpression is common to the majority 
of human cancers, yet attempts to directly target this 
oncogene as a therapeutic strategy have historically 
proven challenging.  This led to the concept that targeting 
essential downstream nodes in the MYC pathway might 
be a more practical goal [61].  However, MYC regulates 
several thousand genes and only a few MYC targets 
are documented as required for the survival of MYC-
overexpressing cells (i.e. essential downstream nodes) 
[13].  Thus, the identification of the essential downstream 
targets, from among the thousands of genes regulated 
by MYC, has also presented a challenge.  Selective 
identification of these essential downstream targets 
was the rationale for the screen in which POLRMT 
was identified (4). The identification of POLRMT as an 
essential downstream effector of MYC subsequently led to 
the observation that MYC overexpression plays a central 
role in controlling the entire gene expression program at 
the mitochondrial genome.  Furthermore, MYC-mediated 
increases in mitochondrial gene expression are critical 
to its ability to drive malignancy and blocking MYC’s 
upregulation of mitochondrial gene expression triggers an 
acute apoptotic response.  Notably, this apoptotic response 
can be triggered by inhibiting MYC’s upregulation of 
mitochondrial gene expression at any of multiple steps, 
using either pharmacologic or genetic approaches.  As 
discussed above, the Amati group recently identified the 
mitochondrial translation factor PTCD3 in an RNAi screen 
specifically designed to identify genes whose inhibition 
results in synthetic lethality with MYC overexpression 
(D’Andrea et al 2016, accompanying paper).  Considering 
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the distinct methodologies and cellular platforms utilized 
across the two studies, the convergent discovery of an 
essential requirement for enhanced mitochondrial gene 
expression adds support to the view that this newly 
identified link is of broad importance for MYC function.
The discovery that MYC controls the full 
mitochondrial transcription program via its direct 
regulation of the nuclear gene encoding the mitochondrial 
RNA polymerase also completes the scenario which began 
to emerge when MYC was documented to play a direct 
Figure 7: Mitochondrial gene expression protects MYC-overexpressing cells from toxic levels of ROS. A. U2OS MYC/
ER cells were infected with lentiviral POLRMT shRNA or Luciferase (Luc) shRNA and treated with NAC. MYC activity was induced via 
4-OHT treatment (MYC On). Three days post-treatment cells were harvested and whole cell lysates were analyzed by Western blot for the 
indicated proteins (left). Relative mRNA expression was measured by qRT-PCR (right). Error bars represent SD, n = 3. B. U2OS MYC/
ER cells were treated with tigecycline (Tig) and/or NAC. MYC activity was induced via 4-OHT treatment. Three days post-treatment cells 
were harvested and whole cell lysates were analyzed by Western blot for the indicated proteins. C. U2OS MYC/ER cells were treated with 
chloramphenicol (CAM). MYC activity was induced via 4-OHT treatment. Whole cell lysates were analyzed by Western blot using an 
antibody cocktail for subunits of electron transport chain (ETC) complexes, as indicated (I-IV). D. U2OS MYC/ER cells were infected with 
lentiviral POLRMT shRNA or Luciferase (Luc) shRNA and treated with MnTBAP. MYC activity was induced via 4-OHT treatment. Three 
days post-treatment cells were harvested. Whole cell lysates were analyzed by Western blot for the indicated proteins. Casp-3, caspase-3; 
FL, full length; CL, cleaved; UT, untreated.
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role in regulating all three RNA polymerase molecules that 
transcribe the nuclear genome (reviewed in [62]).
As mentioned, our own screen was designed to 
exploit the current understanding of the structure/function 
relationship of MYC protein domains.  For many decades 
the highly conserved but functionally enigmatic MbII 
domain was known to be essential for MYC’s ability to 
drive malignancy [63, 64].  We demonstrated that this 
requirement for MbII relates in part to its role in mediating 
interactions between MYC and transcriptional coactivator 
complexes containing the TRRAP acetyltransferase 
partner [65, 66].  Supporting our premise that MYC target 
genes linked to essential MYC functions might require 
the transcriptional cofactors recruited by the similarly 
essential MbII domain, TRRAP itself was identified 
by the Grandori group in a recent RNAi screen for 
genes whose depletion results in synthetic lethality with 
MYC activation [67].  Also consistent with this central 
concept, the two previously characterized MYC targets 
identified in our MbII-based screen, MTA1 and BAG1, 
were subsequently shown to play essential roles in MYC 
function [5, 6].
Mechanistically, a number of distinct biochemical 
defects could provide the explanation for the synthetic 
lethality observed between MYC activation and inhibition 
of mitochondrial gene expression.  For example, Rho0 
cells have a defect in pyrimidine biosynthesis due to 
impairment of the mitochondrial-localized DHODH 
enzyme and can survive only if supplied with exogenous 
sources of pyrimidine [68].  However, exogenous 
pyrimidine did not rescue the synthetic lethality observed 
here (Supplemental Figures S6A-D), suggesting that 
defective pyrimidine biosynthesis/DHODH activity is not 
the primary cause of cell death.  Similarly, experimental 
results have largely eliminated the possibility that MYC’s 
role in one carbon metabolism is the point of vulnerability 
that explains the synthetic lethality (Supplemental Figure 
S6E).  Instead, data support a model in which MYC 
plays a critical role in enhancing mitochondrial function 
and biogenesis, partly via its known role in driving the 
nuclear gene expression program that encodes proteins 
imported into the mitochondria (10), and partly via the 
synchronous upregulation of the mitochondrial gene 
expression program, as reported here.  In this model, 
blockade of the mitochondrial arm of this coordinated 
upregulation, whether by shPOLRMT, shTFB1M, 
2’CMeA, chloramphenicol or tigecycline treatment, results 
in lethality caused by an imbalance in the mitochondrial- 
and nuclear-encoded components of the mitochondria (as 
evident in Figure 7C).  Aberrant subunit stoichiometry 
results in misassembly of ETC complexes, a phenomenon 
known to cause electron leakage and subsequent 
mitochondrial ROS generation [58].  Consistent with this 
model, treatment with the mitochondria specific ROS 
scavenger MnTBAP blocks the synthetic lethal phenotype 
(Figure 7D).  It is also noteworthy that the death observed 
upon POLRMT inhibition in MYC-driven cells is rapid, 
resembling more closely a checkpoint-like phenomenon 
than the cell death associated with the gradual attrition of 
mitochondria as cells proliferate.
Ultimately, these findings have several practical 
and conceptual implications for treatment strategies in 
oncology.  The identification of enhanced mitochondrial 
gene expression as a targetable pathway could be rapidly 
translated into therapeutic approaches by utilizing FDA-
approved compounds that work by mechanisms similar 
to tigecycline.  As mentioned above, tigecycline itself has 
recently completed a Phase I clinical trial for treatment 
of AML (clinicaltrials.gov ID: NCT01332786).  Based on 
TCGA data, MYC is elevated in only 9% of AML patients 
and neither the pre-clinical studies nor the AML clinical 
trial used MYC as a biomarker of tigecycline sensitivity 
[39].  The lack of homology between POLRMT and 
other mammalian RNA polymerase molecules also raises 
the possibility that targeting POLRMT with inhibitors 
mechanistically related to 2’CMeA could also prove 
efficacious and selective.  The fact that all tested strategies 
for inhibiting mitochondrial gene expression have effects 
only when MYC is simultaneously expressed at oncogenic 
levels, provides optimism that a therapeutic window might 
exist between lethal effects of these treatments on tumor 
cells and toxicity in non-malignant cells.  This principle 
appears broadly applicable since the synthetic lethality 
was observed in cells of many distinct lineages where 
oncogenic MYC levels were achieved by a variety of 
means.  Also providing optimism for these findings having 
broad implications are the data showing that the synthetic 
lethality can be observed even in tumor cells lacking 
functional p53.
Recent efforts in the design of direct and indirect 
MYC inhibitors aim to decrease MYC expression/
function as a therapeutic strategy [69-72]. In contrast, the 
findings reported here suggest that exploiting the potent 
apoptotic activity provided by MYC overexpression for a 
therapeutic advantage might be more advantageous.  High 
expression (i.e. oncogenic) levels of MYC are required 
for apoptosis [73, 74], offering a unique opportunity to 
specifically target cancer cells.  The approach of exploiting 
oncogene overexpression, rather than inhibiting oncogenic 
signaling pathways, offers a distinct perspective on the 
design of cancer therapies.
MATERIALS AND METHODS
Cell culture
Cell lines were obtained from ATCC. All cells, with 
the exception of Raji and IMR90 cells, were maintained 
in Dulbecco’s modified Eagle’s medium (DMEM) 
(Corning) supplemented with 10% fetal bovine serum 
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(FBS) (Gemini). Raji cells were maintained in RPMI 
1640 (Corning) supplemented with 10% FBS and 1% 
L-glutamine (Corning). IMR90 cells were maintained in 
Eagle’s minimum essential medium (EMEM) (Corning) 
supplemented with 2mM L-glutamine, 1% nonessential 
amino acids (Corning) and 10% FBS.
The MYC/ER fusion protein was activated by 
adding 4-hydroxytamoxifen (4-OHT) (Sigma Aldrich) at 
a final concentration of 30nM. JQ1 was used as previously 
described [75]. The 2’C-methyladenosine (2’CMeA) was 
a generous gift of Dr. Joy Feng and Gilead Sciences, Inc 
and was added to cell media at concentrations ranging 
from 3-30µM. The antibiotics chloramphenicol and 
tigecycline were used at concentrations ranging from 
13-120µg/mL and10µM, respectively (Sigma Aldrich). 
The ROS scavenger N-acetylcysteine (NAC) was 
used at a concentration of 5mM (Sigma Aldrich). The 
mitochondrial-specific ROS scavenger MnTBAP was used 
at a concentration of 100nM (MED Millipore). Exogenous 
uridine and pyruvate were used at concentrations of 50µg/
mL and 100µg/mL, respectively (Sigma Aldrich).
Plasmid expression and lentiviral production
MYC siRNA was obtained from Dharmacon. 
GFP siRNA was used as a negative control. Cells were 
transfected with 200 nM siRNA per well in 6-well 
plates using DharmaFECT 2 (Dharmacon). Cells were 
harvested and RNA and protein extracted 72 hours after 
transfection. The Plv-based lentiviral expression of human 
POLRMT was obtained from Dr. Chumakov. Lentiviral 
short hairpin RNA (shRNA) plasmids corresponding to 
MYC, POLRMT, TFB1M, SHMT2 and control luciferase 
shRNAs were obtained from TRC (Sigma). See below 
table for shRNA sequences. All sequences are from listed 
5’-3’. Lentiviral packaging plasmids (pCMV-R8.2 and 
pCMV-VSV-G) were cotransfected with vectors into 293T 
Target TRCN Sequence
MYC 0000039642 CCGGCCTGAGACAGATCAGCAACAACTCGAGTTGTTGCTGATCTGTCTCAGGTTTTTG
POLRMT-1 0000053114 CCGGCGGTGGATGTACCCATGCTTTCTCGAGAAAGCATGGGTACATCCACCGTTTTTG
POLRMT-2 0000053113 CCGGGCAGAACCACTACAGGAAGTACTCGAGTACTTCCTGTAGTGGTTCTGCTTTTTG
PTCD3 0000145035 CCGGGCTGATATCAAATCTGCGTATCTCGAGATACGCAGATTTGATATCAGCTTTTTTG
SHMT2 0000034807 CCGGGCTCCAGGATTTCAAATCCTTCTCGAGAAGGATTTGAAATCCTGGAGCTTTTTG
TFB1M 0000021041 CCGGCCACGATTCGAGAAATCATTACTCGAGTAATGATTTCTCGAATCGTGGTTTTT
Human Gene Forward Primer Reverse Primer
12S AAAACTGCTCGCCAGAACACTAC GCACCCCCAGGTCCTTT
ATP6 TCATTCAACCAATAGCCCTGG GCCTGCAGTAATGTTAGCGGT
CAD TCAAAAGGTGTCCAGTGGGC GACAATTCCCAGCCACATGC
CytB CGCATGATGAAACTTCGGCT ATTTGGAGGATCAGGCAGGC
HBO1 TCATGATGAGTCACCGCCTC TCAGAAGAAGGCGCATTTCC
MYC GGACGACGAGACCTTCATCAA GCCGCTCCACATACAGTCCT
ND2 GGTTGCTTGCGTGAGGAAAT AACCCTCGTTCCACAGAAGCT
ND4 CCTAAAGCCCATGTCGAAGC TGCGGCAAGTACTATTGACCC
PCAF ACCCTAACCCCTCACCCACT CAATTATTTGCTGCAGGTCGG
POLRMT CGGGTCCCCGAGAACATC GGGAGGCCTCTCACTATCTCGTA
SHMT2 CAAGACTGGCCGGGAGATC GGGAACACGGCAAAGTTGAT
SMYD2 TCATAGCTGTTGCCCCAATG TCTGCCAGGGTCCCTTTGTA
TFB1M TGCTTGCCGCGTATCATG CGGAGGGAGACGGCAAGT
POLRMT-1 (ChIP) GCTTTCTCTCCTTGCAGCCTC GCTGGAAGACACAGCACGTG
POLRMT-2 (ChIP) GGAGTCTACTTCCGGCTGGG GTGGTTTCATGGTCGACG
POLRMT-3 (ChIP) TGCCTTGAGCATTTCCTTCC CCAGACAGATTCACGAGCCC
POLRMT-4 (ChIP) CCGCGATGTGTGGTTAGATCT GATTCTGCTGGAACGACCTCC
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cells. Viral supernatants were collected, filtered, and added 
directly to target cells in the presence of 8µg/ml polybrene 
(Sigma Aldrich). Cells were selected with puromycin 
(Sigma Aldrich) for 24 hours. The yDHODH retroviral 
vector was constructed in the packaging vector MIGR1. 
Retroviral packaging plasmid Ψ2 was cotransfected with 
yDHODH or empty vector into U2OS MYC/ER cells in 
the presence of 8µg/mL polybrene. Transfected cells were 
isolated by fluorescence-activated cell sorting (FACS) for 
the GFP marker expressed from the retroviral vector, 2-3 
days post-transfection. 
Quantitative RT-PCR and chromatin 
immunoprecipitation
Quantitative RT-PCR (qRT-PCR) was performed 
by real-time analysis using the Step One Plus detection 
system (Applied Biosystems) and SYBR GREEN PCR 
Master Mix kit (Applied Biosystems). RNA was isolated 
using the Trizol method (Invitrogen) and cDNA was 
then generated using the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems). 
ChIP was performed as described previously [5], 
using chromatin from the primary human fibroblast strain 
2091. See below table for primer sequences. All sequences 
are listed from 5’-3’.
Western blotting
To generate whole cell extracts, cells were lysed 
with E1A lysis buffer (20mM NaH2PO4, 150mM NaCl, 
0.5% IGEPAL, 5mM EDTA, 50mM NaF, 30mM Sodium 
pyrophosphate, 10% Glycerol). The following antibodies 
were used to detect protein expression by Western blot, 
MYC, actin, p53, H2B (Santa Cruz), POLRMT, Total 
OXPHOS Cocktail (Abcam), Caspase-3 (Cell Signaling), 
PARP (Biovision), γH2A.X (Millipore), and ORC2 (BD 
Bioscience). Western blotting of mitochondrial isolates for 
the mitochondrial proteins POLRMT, TFAM, HSP60 and 
porin has been described previously [7].
mtDNA quantitation
DNA was collected from whole cell lysates. qPCR 
was performed for genomic sequences of the mitochondrial 
encoded genes cytochrome c oxidase subunit 1 (COX1), 
NADH dehydrogenase subunit 2 (ND2), ATP synthase 
6 (ATP6), NADH dehydrogenase subunit 4 (ND4), 12S 
rRNA, and the nuclear gene peroxisome proliferative 
activated receptor gamma coactivator- related 1 (PPRC1). 
Absolute COX1, ND2, ATP6, ND4 and 12S DNA 
copies were normalized to nuclear genome content, as 
represented by PPRC1 signals. As a control, a nuclear 
genome sequence at 3p24 was amplified. 
Proliferation assay
2x105 U2OS MYC/ER cells were plated in complete 
medium. After attachment of cells to tissue culture dishes 
(approximately 24 hours), cells were treated with 4-OHT 
as described above. Cells were harvested and counted by 
hemocytometer after 3 and 5 days of treatment.
Apoptosis assays
To quantitate apoptotic cell death, cells were 
collected by trypsinization, washed with phosphate-
buffered saline and stained using the Annexin V PE-
7AAD apoptosis detection kit (BD Pharmingen) as 
described previously [76]. Fluorescence was detected by 
flow cytometry (BD LSRII) and analyzed using FlowJo 
software (TreeStar). 10,000 total events were collected and 
then subsequently analyzed for the percentage of Annexin 
V-PE positive cells.
ROS assay
To quantitate levels of reactive oxygen species, cells 
were collected by trypsinization, washed with phosphate-
buffered saline, and counted. 200,000 cells were stained 
with MitoSOX Red Mitochondrial Superoxide Indicator 
(Thermo Fisher). Fluorescence was detected by flow 
cytometry (BD LSRII) and analyzed using FlowJo 
software (TreeStar). 10,000 total events were collected.
Mice
Female bitransgenic MMTV-rtTA;TetO-MYC 
mice [16, 77] were administered 2 mg/mL doxycycline 
in drinking water beginning at 6 weeks of age to induce 
c-MYC expression in mammary tissue and mice were 
palpated weekly to identify mammary tumors. Mammary 
tumors were harvested from mice on doxycycline, 
as well as from tumor-bearing mice following 96 hr 
of doxycycline withdrawal to induce c-MYC down-
regulation. Tumor tissue was snap frozen and RNA was 
extracted and purified as described above. 
C57Bl/6 mice (6-11 weeks old) were injected 
(intravenous, tail vein) with 2x106 Eµ-myc lymphoma 
cells expressing GFP. Tigecycline (100 mg/kg) or PBS 
(vehicle control) was injected (intraperitoneal) twice 
daily for 3 days followed by once daily for 11 days. 
Treatment commenced the day of lymphoma injection 
for one cohort of mice (n = 9 per group) or in a second 
cohort (n = 12 per group), once the lymphoma had 
established (day 9) as determined by elevated (~9-10x103 
cells/ml) white blood cell counts. Blood was collected 
at intervals to measure white blood cell counts (WBC) 
using a FORCYTE Analyzer (Oxford Science) and the 
Oncotarget72411www.impactjournals.com/oncotarget
percentage of GFP positive lymphoma cells using flow 
cytometry (see below). All mice were carefully monitored 
and sacrificed at humane endpoints as the lymphoma 
progressed. All surviving mice were sacrificed on day 
129 or 126 following lymphoma injection for the first 
or second cohort, respectively. Kaplan-Meier analyses 
were performed and log-rank tests determined statistical 
significance for survival (GraphPad Prism).
Whole blood (30 ml) was drawn from each mouse 
at intervals. Following hypotonic lysis of red blood 
cells, GFP positive cells (lymphoma) were measured by 
flow cytometry (BD FACSCanto II) and analyzed using 
FlowJo software (TreeStar). Lymph nodes were removed 
from surviving mice at the end of the study. Single cell 
suspensions were prepared from the lymph nodes and 
subjected to flow cytometry. 
Oncomine microarray datasets
Gene expression of MYC, POLRMT, LDHA and 
BAG1 was analyzed using microarray gene expression 
datasets deposited in the Oncomine Cancer Profiling 
Database (www.oncomine.org). Each gene was queried 
individually and Primary Filters were set to Analysis 
Type: Cancer vs. Normal Analysis. The Basso Lymphoma 
dataset comparing Burkitt’s Lymphoma vs. Normal was 
used to display gene expression values. Additional datasets 
used to compare MYC and POLRMT expression include 
Skryzpczak Colorectal 2, Sabates-Bellver Colon, and 
Zhan Myeloma.
UCSC genome browser
MYC binding sites at the POLRMT locus were 
identified using the UCSC Genome Browser Assembly 
GRCh37/hg19 with a display of the track for Transcription 
Factor ChIP-seq Uniform Peaks from ENCODE [23, 24].
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